Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents

IF 3.8 2区医学 Q1 HEMATOLOGY British Journal of Haematology Pub Date : 2025-02-26 DOI:10.1111/bjh.20012

Sara Mato, Lorenzo Carità, Ariadna Colmenero, Mara Andrés, Olga Balagué, Maitane Andión, Itziar Astigarraga, Verónica Celis, Carmen Mendoza, Pilar Guerra-García, Lorena Valero, Ana Galera, María Tallón, Melina Pol, Natalia Castrejón-de-Anta, Leonie Frauenfeld, Noelia Garcia, Elías Campo, Itziar Salaverria, Jaime Verdú-Amorós

{"title":"Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents","authors":"Sara Mato, Lorenzo Carità, Ariadna Colmenero, Mara Andrés, Olga Balagué, Maitane Andión, Itziar Astigarraga, Verónica Celis, Carmen Mendoza, Pilar Guerra-García, Lorena Valero, Ana Galera, María Tallón, Melina Pol, Natalia Castrejón-de-Anta, Leonie Frauenfeld, Noelia Garcia, Elías Campo, Itziar Salaverria, Jaime Verdú-Amorós","doi":"10.1111/bjh.20012","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>The outcome of B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents has improved significantly over recent decades due to risk-adapted strategies and the use of immunotherapy. However, refractory or relapsed (R/R) B-NHL remains extremely difficult to cure (<30%). This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of <i>TP53</i> as a biomarker in R/R B-NHL. <i>TP53</i> mutations were identified in 44% of tumours and associated with a worse 3-year overall survival (15% vs. 80%; <i>p</i> = 0.048).</p>\n </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 5","pages":"1390-1396"},"PeriodicalIF":3.8000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.20012","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The outcome of B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents has improved significantly over recent decades due to risk-adapted strategies and the use of immunotherapy. However, refractory or relapsed (R/R) B-NHL remains extremely difficult to cure (<30%). This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of TP53 as a biomarker in R/R B-NHL. TP53 mutations were identified in 44% of tumours and associated with a worse 3-year overall survival (15% vs. 80%; p = 0.048).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

儿童和青少年复发难治性成熟b细胞非霍奇金淋巴瘤的综合分析。

近几十年来，由于风险适应策略和免疫治疗的使用，儿童和青少年b细胞非霍奇金淋巴瘤（B-NHL）的预后显著改善。然而，难治性或复发（R/R） B-NHL仍然极难治愈。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.